DJIA 18,011.94 -28.43 -0.16%
NASDAQ 5,076.52 0.00 0.00%
S&P 500 2,109.60 -2.13 -0.10%
market minute promo

MannKind Corp (NASDAQ: MNKD)

5.22 0.06 (1.16%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

MNKD $5.22 1.16%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.16
Previous Close $5.16
Daily Range $5.10 - $5.29
52-Week Range $3.46 - $11.48
Market Cap $2.1B
P/E Ratio -11.47
Dividend (Yield) $0.00 (0.0%)
Volume 4,491,898
Average Daily Volume 7,789,400
Current FY EPS -$0.31

Sector

Healthcare

Industry

Drug Makers

MannKind Corp (MNKD) Description

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer. Website: http://www.mannkindcorp.com/

News & Commentary Rss Feed

MannKind Corporation Shares Skyrocketed in May -- Here's Why

MannKind investors breathe a bit easier in May after Wall Street commentary eases their pain. Could this rally continue, or are skeptics still in firm control?

Lessons I Learned From Owning MNKD

What To Expect When Afrezza Goes Direct To Consumer

5 Key Analyst Stock Picks With 50% To 100% Upside (Or Even More)

Is MannKind a Buy?

After exploring MannKind's past, present, and future, it's time to ask: Is MannKind a buy now?

MNKD July 10th Options Begin Trading

Wednesday's ETF Movers: BBH, XOP

How Will Big Pharma Fight Back Against MannKind?

Afrezza, an inhaled insulin, is officially on the market, and threatens many big industry leaders. How will big pharma fight back against the inhaled insulin threat?

Could Incoming Threats Sink MannKind Corporation?

Big Pharma suspected that MannKind's Afrezza would make its way to the market eventually. Now that its here, what does the industry have in its pipeline that could potentially slow adoption?

Interesting MNKD Put And Call Options For July 2nd

See More MNKD News...

MNKD's Top Competitors

MNKD $5.22 (1.16%)
Current stock: MNKD
AMGN $156.44 (-0.38%)
Current stock: AMGN
GILD $113.94 (-0.12%)
Current stock: GILD
BIIB $387.62 (-1.46%)
Current stock: BIIB